Pfenex Inc. (NYSE American: PFNX) announced today it has successfully completed the PF708 comparative use human factors (HF) study and submitted the final study report to the FDA. The study found that the user interface of the FDA-approved PF708 product was noninferior to that of Forteo® for each critical user task evaluated in the study.
Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements for PF708 with PharmBio Korea in South Korea, JAMP Pharma in Canada and Kamada Ltd. in Israel.
Congressman Anthony Brindisi continued his efforts to bring down drug costs by joining Reps. Scott Peters (CA-52) and Pete King (NY-02) to introduce the bipartisan Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars (ACCESS) Act.
Although biosimilars lack clinically meaningful differences in therapeutic activity as compared to the originator product, these complex biological molecules are not considered identical chemical copies, unlike generics, and minor differences in molecular structure and inactive compounds may exist.
Oncology biosimilars are biologic agents that are highly similar to the originator biologic medicine, which is already approved by the U.S. FDA without clinically meaningful differences in terms of efficacy, safety, and purity with reference agents. Increasing the prevalence of cancer due to an unhealthy lifestyle and the rising number of U.S. FDA approvals of biosimilars are the factors boosting the oncology biosimilars market.
Biocon Limited (Biocon Ltd) and Evotec SE recently announced that Biocon Biologics, a wholly owned subsidiary of Biocon Ltd, and Just - Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical biosimilar asset.
Bipartisan introduction of legislation from Representatives Tonko and Gibbs will direct the U.S. Department of Health & Human Services (HHS) to create a biosimilar access measure in the Centers for Medicare & Medicaid Services’ (CMS) Star Ratings Program.
Samsung Bioepis Co., Ltd. recently announced real-world data of BENEPALI in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Two of Canada's leading patient groups, the Gastrointestinal Society and the Canadian Society of Intestinal Research (CSIR), are calling on patients with inflammatory bowel disease (IBD) to participate in a survey to help them identify what's missing in their care. They are also asking Canadian patients with any inflammatory condition who take biologic/biosimilar medication to provide their opinions.
Therapeutically more effective drugs for the treatment of chronic diseases represents a crucial need. Biosimilars and biobetters offer the possibility to lower the cost of treating a variety of chronic diseases.
|
|
|
|
|
|
|
|
|